Patents Assigned to The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
  • Patent number: 11492414
    Abstract: Monoclonal antibodies, or antigen-binding fragments thereof, that bind to ERG, and more specifically, to an epitope formed by amino acids 42-66 of ERG3 are disclosed. The monoclonal antibodies can be non-human antibodies (e.g., rabbit or mouse) or humanized monoclonal antibodies having the CDR regions derived from those non-human antibodies. In other embodiments, the monoclonal antibodies are chimeric, having the light and heavy chain variable regions of a non-human ERG antibody. Methods of using the antibodies to detect ERG, or fusion proteins comprising all or part of an ERG polypeptide, such as an ERG polypeptide encoded by a TMPRSS2/ERG, SLC45A3/ERG, or NDRG1/ERG fusion transcript, are also provided, including methods of detecting ERG or ERG fusion events in a clinical setting.
    Type: Grant
    Filed: February 15, 2019
    Date of Patent: November 8, 2022
    Assignee: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
    Inventors: Shiv Srivastava, Shyh-Han Tan, Albert Dobi
  • Publication number: 20220326257
    Abstract: Described herein are deiminated proteins that are deiminated in response to oxygen-deprivation brain injury (ODBI) and/or oxygen-deprivation causing injury (ODCI). Also described are related methods and devices for detecting, diagnosing, and monitoring ODBI or ODCI, and methods for treating ODBI or ODCI.
    Type: Application
    Filed: April 30, 2019
    Publication date: October 13, 2022
    Applicant: THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC.
    Inventor: Gregory P. MUELLER
  • Patent number: 11426069
    Abstract: Provided are methods and system for assessing a human subject's neurological and/or psychological status. The methods entail displaying visual tests to a human subject, wherein each of the visual tests includes a visual target signal, optionally with visual cue signals, for eliciting visual and, optionally, body part, movements by the subject. Following the display, the movements are then detected. The latency and/or correctness of such movements can then be used to assess the subject's neurological and/or psychological status. Also provided are methods and systems for assessing performance validity.
    Type: Grant
    Filed: March 10, 2014
    Date of Patent: August 30, 2022
    Assignee: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
    Inventors: Mark L. Ettenhofer, David Barry
  • Publication number: 20220257266
    Abstract: An intracranial access device includes a housing having an operator-facing side and a patient-facing side and an opening therethrough extending from the operator-facing side to the patient-facing side. The device further includes at least one fastener configured to secure the device to a cranium of a patient. The device further includes a drill mounted to a surface of the housing and a cauterizer. The device may further include a number of sensors arranged on the patient-facing side of the housing and configured to identify a hemorrhage location.
    Type: Application
    Filed: July 16, 2020
    Publication date: August 18, 2022
    Applicants: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., The Johns Hopkins University
    Inventors: David L. Brody, David Blodgett, Carissa Rodriguez, Timothy Sleasman, Michael J. Fitch, Adam Cohen, Max R. Basescu, Kevin C. Wolfe, Jared M. Wormley
  • Patent number: 11345653
    Abstract: The invention relates to compounds, compositions and methods for activating, reactivating, reversing or preventing the deactivation of cholinesterases, such as acetylcholinesterase and butyrylcholinesterase.
    Type: Grant
    Filed: June 16, 2017
    Date of Patent: May 31, 2022
    Assignees: The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc., The Government of the United States as Represented by the Secretary of the Army
    Inventors: Ilja Khavrutskii, Sven Anders Wallqvist
  • Publication number: 20220160855
    Abstract: The invention relates to pharmaceutical compositions comprising at least one antigen and an adjuvant composition, where the adjuvant composition comprises a saponin and a liposome. The liposome of the composition comprises monophosphoryl lipid A (MPLA), cholesterol and a phospholipid that is in a liquid crystalline state at greater than or equal to 23° C., and the concentration of cholesterol to lipid in the liposome is greater than 50% (mol/mol). The antigen in the composition is a soluble Plasmodium falciparum recombinant circumsporozoite protein (rCSP) comprising the amino acid sequence of SEQ ID NO:1, or a P. falciparum rCSP peptide that is at least 95% identical to the amino acid sequence of SEQ ID NO:1.
    Type: Application
    Filed: April 27, 2018
    Publication date: May 26, 2022
    Applicant: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
    Inventors: Sheetij Dutta, Zoltan Beck, Carl Alving, Gary Matyas
  • Patent number: 11338025
    Abstract: The present invention provides methods of preventing or reducing the risk of recurrence of endometrial and ovarian cancers which express low levels of folate binding protein (FBP) by administration of a vaccine containing an E39 peptide.
    Type: Grant
    Filed: January 16, 2018
    Date of Patent: May 24, 2022
    Assignee: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
    Inventor: George E. Peoples
  • Patent number: 11332517
    Abstract: The present invention relates to antibodies or antibody fragments that bind, neutralize, and/or inhibit Hendra or Nipah virus. The invention provides antibodies or antibody fragments that selectively bind to the F glycoprotein of Hendra or Nipah virus, and pharmaceutical compositions including such antibodies and/or fragments. The invention further provides polynucleotides encoding the antibodies and fragments of the invention and host cells transformed therewith. Additionally, the invention discloses prophylactic, therapeutic, and diagnostic methods employing the antibodies, fragments, polynucleotides, and/or compositions of the invention.
    Type: Grant
    Filed: August 10, 2020
    Date of Patent: May 17, 2022
    Assignee: THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC.
    Inventors: Yee-Peng Chan, Christopher C. Broder
  • Publication number: 20220105186
    Abstract: This invention encompasses methods of preserving protein function by contacting a protein with a composition comprising one or more purine or pyrimidine nucleosides (such as e.g., adenosine or uridine) and an antioxidant (such as e.g., manganese). In addition, the invention encompasses methods of treating and/or preventing a side effect of radiation exposure and methods of preventing a side effect of radiotherapy comprising administration of a pharmaceutically effective amount of a composition comprising one or more purine or pyrimidine nucleosides (such as e.g., adenosine or uridine) and an antioxidant (such as e.g., manganese) to a subject in need thereof. The compositions may comprise D. radiodurans extracts.
    Type: Application
    Filed: November 2, 2021
    Publication date: April 7, 2022
    Applicants: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., The Government of the USA as Represented by the Secretary Department of Health and Human Services
    Inventors: Michael J. Daly, Elena K. Gaidamakova, Vera Y. Matrosova, Rodney L. Levine, Nancy B. Wehr
  • Patent number: 11291637
    Abstract: The invention relates to methods of treating or preventing organophosphate poisoning in a subject in need thereof, comprising administering to the subject isoflurane, enflurane, halothane, sevoflurane, desflurane, xenon or argon in a therapeutically effective amount.
    Type: Grant
    Filed: September 18, 2017
    Date of Patent: April 5, 2022
    Assignee: THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC.
    Inventors: Jishnu K. S. Krishnan, Aryan M. Namboodiri, John R. Moffett, Peethambaran Arun, Narayanan Puthillathu, Ranjini Vengilote
  • Publication number: 20220098284
    Abstract: Antibodies and compositions of matter useful for the detection, diagnosis and treatment of Epstein Barr Virus infection in mammals, and methods of using those compositions of matter for the same are disclosed. Also disclosed are proteins, referred to as anti-gp350 antibody probes, and anti-gp350 B-cell probes, that maintain the epitope structure of the CR2-binding region of gp350, but do not bind CR2.
    Type: Application
    Filed: December 16, 2021
    Publication date: March 31, 2022
    Applicants: The U.S.A., as represented by the Secretary, Department of Health and Human Services, The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
    Inventors: Wei Bu, Masaru Kanekiyo, Michael Gordon Joyce, Jeffrey I. Cohen
  • Patent number: 11242572
    Abstract: The present disclosure is directed towards a virus, called Cedar Virus, and its methods of use.
    Type: Grant
    Filed: March 12, 2019
    Date of Patent: February 8, 2022
    Assignee: THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC.
    Inventors: Linfa Wang, Glenn A. Marsh, Hume Field, Christopher Broder
  • Patent number: 11236395
    Abstract: The present invention relates to oncogenes or tumor suppressor genes, as well as other genes, involved in prostate cancer and their expression products, as well as derivatives and analogs thereof. Provided are therapeutic compositions and methods of detecting and treating cancer, including prostate and other related cancers. Also provided are methods of diagnosing and/or prognosing prostate cancer by determining the expression level of at least one prostate cancer-cell-specific gene, including, for example, the ERG gene or the LTF gene alone, or in combination with at least one of the AMACR gene and the DD3 gene.
    Type: Grant
    Filed: May 11, 2018
    Date of Patent: February 1, 2022
    Assignee: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
    Inventors: Gyorgy Petrovics, Shiv Srivastava
  • Patent number: 11236151
    Abstract: Antibodies and compositions of matter useful for the detection, diagnosis and treatment of Epstein Barr Virus infection in mammals, and to methods of using those compositions of matter for the same. Also disclosed are proteins, referred to as anti-gp350 antibody probes, and anti-gp350 B-cell probes, that maintain the epitope structure of the CR2-binding region of gp350, but do not bind CR2.
    Type: Grant
    Filed: April 25, 2018
    Date of Patent: February 1, 2022
    Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
    Inventors: Wei Bu, Masaru Kanekiyo, Michael Gordon Joyce, Jeffrey I. Cohen
  • Publication number: 20210393615
    Abstract: Described are methods of treating or reducing the toxic effects of exposure to a nerve agent, comprising administering to a subject in need thereof (i) an AMPA/GluR5(GluK1) kainate receptor antagonist (such as LY293558) and (ii) an NMD A receptor antagonist (such as an antimuscarinic compound, such as caramiphen), as well as methods of treating, reducing the risks of, or preventing a neurological condition such as epilepsy, seizures, post-traumatic stress disorder, status epilepticus, depression, or anxiety, comprising administering to a subject in need thereof (i) an AMPA/GluR5(GluK1) kainate receptor antagonist (such as LY293558) and (ii) an NMDA receptor antagonist (such as an antimuscarinic compound, such as caramiphen). The methods may further comprise administering a positive allosteric modulator of synaptic GABAA receptors, such as a benzodiazepine, such as midazolam, to the subject. The methods are suitable for use in children and adults. Related compositions and uses also are described.
    Type: Application
    Filed: June 28, 2021
    Publication date: December 23, 2021
    Applicant: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
    Inventors: Maria F. BRAGA, Vassiliki ARONIADOU-ANDERJASKA
  • Publication number: 20210277475
    Abstract: The present invention relates to methods of diagnosing traumatic brain injury (TBI) in a subject. The present invention also relates to methods of monitoring the progression of the TBI in a subject.
    Type: Application
    Filed: April 8, 2021
    Publication date: September 9, 2021
    Applicants: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., University of Florida Research Foundation, Inc., Orlando Health, Inc., d/b/a Orlando Regional Medical Center
    Inventors: Radha K. MAHESHWARI, Nagaraja S. BALAKATHIRESAN, Manish BHOMIA, Kevin K. WANG, Linda PAPA
  • Patent number: 11090373
    Abstract: Described herein are agents and methods for targeting antigen-specific B cells using engineered T cells, such as regulatory T cells or cytotoxic T cells, or bi-specific antibodies. The agents and methods can be used to reduce undesirable immune responses.
    Type: Grant
    Filed: October 6, 2016
    Date of Patent: August 17, 2021
    Assignee: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
    Inventors: David W. Scott, Yongchan Kim, Aihong Zhang
  • Patent number: 11085934
    Abstract: The invention relates to methods of determining if a subject is at risk of developing post-traumatic stress disorder (PTSD).
    Type: Grant
    Filed: October 6, 2016
    Date of Patent: August 10, 2021
    Assignee: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
    Inventors: Harvey B. Pollard, Clifton L. Dalgard
  • Publication number: 20210238262
    Abstract: The invention described herein provides antibodies to Zika virus. The novel polypeptides are useful alone or as portions of larger molecules, such as antibodies or antibody fragments, that can be used to treat or prevent infection of Zika virus.
    Type: Application
    Filed: April 24, 2019
    Publication date: August 5, 2021
    Applicants: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., The Beth Israel Deaconess Medical Center, Inc., The Government of the United States as Represented by the Secretary of the Army
    Inventors: Shelly Krebs, Gina Donofrio, Vincent Dussupt, Kayvon Modjarrad, Dan Barouch, Richard G. Jarman, III, Nelson L. Michael, Gordon Joyce
  • Publication number: 20210230230
    Abstract: This invention relates to soluble forms of G glycoprotein from Hendra and Nipah virus. In particular, this invention relates to compositions comprising soluble forms of G glycoprotein from Hendra and Nipah virus and also to diagnostic and therapeutic methods using the soluble forms of G glycoprotein from Hendra and Nipah virus. Further, the invention relates to therapeutic antibodies including neutralizing antibodies, and vaccines for the prevention and treatment of infection by Hendra and Nipah viruses.
    Type: Application
    Filed: January 29, 2021
    Publication date: July 29, 2021
    Applicant: THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC.
    Inventors: Christopher C. Broder, Katharine N. Bossart